Multiple Myeloma Clinical Trial

Clinical Trial Finder Multiple Myeloma Trials

A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

See Locations Near You

Summary

To assess the safety and tolerability, characterize the dose limiting toxicities (DLTs) and identify the maximally tolerated dose (MTD) of Elotuzumab administered in combination with either Lirilumab or Urelumab in subjects with multiple myeloma.

View Full Description

Full Description

Allocation:

Part1: Non-randomized
Part2: Randomized

View Eligibility Criteria

Eligibility Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

Subjects must have histological confirmation of multiple myeloma with measurable disease (per International Myeloma Working Group (IMWG) criteria):

Relapsed/refractory multiple myeloma, subjects who are post autologous transplant and have achieved very good partial response (VGPR) or complete response (nCR) with minimal residual disease (MRD)

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

44

Study ID:

NCT02252263

Recruitment Status:

Completed

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 6 Locations for this study

See Locations Near You

University Of Arkansas For Medical Sciences
Little Rock Arkansas, , United States
The Sidney Kimmel Comprehensive Cancer Center
Baltimore Maryland, 21287, United States
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States
The Ohio State University
Columbus Ohio, 43210, United States
Oregon Health & Science University
Portland Oregon, 97239, United States
University Of Pennsylvania
Philadelphia Pennsylvania, 19104, United States
Local Institution
Pamplona Navarra, 31008, Spain
Load More

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

44

Study ID:

NCT02252263

Recruitment Status:

Completed

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials Can be Life-Saving for Some
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider